Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: Results on toxicity, side effects and quality-of-life

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 1, 2010, Pages 97-101

  Ploussard, G ^a   Paule, B ^a   Salomon, L ^a   Allory, Y ^a   Terry, S ^a   Vordos, D ^a   Hoznek, A ^a   Vacherot, F ^a   Abbou, C C ^a   Culine, S ^a   De La Taille, A ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Adjuvant chemotherapy; High risk; Paclitaxel; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; GONADORELIN; GONADORELIN AGONIST; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EPISTAXIS; ERECTILE DYSFUNCTION; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; HEART LEFT VENTRICLE FAILURE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LUNG INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; THROMBOCYTOPENIA; THROMBOEMBOLISM; URINARY TRACT INFECTION; URINE INCONTINENCE;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PILOT PROJECTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; URINARY INCONTINENCE;

EID: 76949108177     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.51     Document Type: Article

References (23)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-249.
2. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after prostatectomy for prostate cancer. J Clin Oncol 1999; 17: 1499-1507.
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-914.
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974. (Pubitemid 28445094)
5. Messing E M, Manola J, Sarosdy M, Wilding G, Crawford E D, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781-1788.
6. Messing E M, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006; 7: 472-479.
7. McLeod D G, Iversen P, See WA, Morris T, Armstrong J, Wirth M P. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247-254.
8. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al. Long-term followup of a randomized trail of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-794.
9. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol 2009; 181: 956-962.
10. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
11. Tannock IF, deWit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512.
12. Kibel A S, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007; 177: 1777-1781.
13. Cetnar JP, Malkowicz SB, Palmer SC, Wein AJ, Vaughn DJ. Pilot trial of adjuvant paclitaxel plus estramustine in resected highrisk prostate cancer. Urology 2008; 71: 942-946.
14. Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S et al. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy After Prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 2008; 72: 474-480.
15. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007; 110: 2628-2639.
16. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138-1142. (Pubitemid 38746819)
17. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2004; 11: 5233-5240.
18. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335.
19. Sokoloff MH, Rinker-Schaeffer CW, Chung LWK, Brendler CB. Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells. J Urol 2004; 172: 2539-2544.
20. Roth B J, Yeap B Y, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72: 2457-2460.
21. Trivedi C, Redman B, Flaherty LE, Kucuk O, DuW, Heilbrun LK et al.Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 2000; 89: 431-436.
22. Salomon L, Anastasiadis AG, Katz R, De La Taille A, Saint F, Vordos D et al. Urinary continence and erectile function: a prospective evaluation of functional results after laparoscopic prostatectomy. Eur Urol 2002; 42: 338-343.
23. Salomon L, Saint F, Anastasiadis AG, Sèbe P, Chopin D, Abbou CC. Combined reporting of cancer control and functional results of radical prostatectomy. Eur Urol 2003; 44: 656-660. (Pubitemid 37542922)